USRE39861E1 - Methods of extended use oral contraception - Google Patents

Methods of extended use oral contraception Download PDF

Info

Publication number
USRE39861E1
USRE39861E1 US10/893,795 US89379504A USRE39861E US RE39861 E1 USRE39861 E1 US RE39861E1 US 89379504 A US89379504 A US 89379504A US RE39861 E USRE39861 E US RE39861E
Authority
US
United States
Prior art keywords
estrogen
progestin
days
norethindrone acetate
ethinyl estradiol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US10/893,795
Inventor
Gary D. Hodgen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Barr Pharmaceuticals Inc
Teva Womens Health Inc
Original Assignee
Duramed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32043766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=USRE39861(E1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duramed Pharmaceuticals Inc filed Critical Duramed Pharmaceuticals Inc
Assigned to BARR LABORATORIES, INC. reassignment BARR LABORATORIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EASTERN VIRGINIA MEDICAL SCHOOL
Assigned to DURAMED PHARMACEUTICALS, INC. reassignment DURAMED PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BARR LABORATORIES, INC.
Application granted granted Critical
Publication of USRE39861E1 publication Critical patent/USRE39861E1/en
Assigned to TEVA WOMEN'S HEALTH, INC. reassignment TEVA WOMEN'S HEALTH, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: DURAMED PHARMACEUTICALS, INC.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Definitions

  • the ovarian/menstrual cycle is a complex event characterized by an estrogen rich follicular phase and, after ovulation, a progesterone rich luteal phase. Each has a duration of approximately 14 days resulting in an intermenstrual interval of about 28 days.
  • the endometrial tissue responds to the changes in hormonal milieu.
  • the onset of menstruation is the beginning of a new menstrual cycle and is counted as day 1.
  • the superficial layers of the endometrium which grew and developed during the antecedent ovarian/menstrual cycle, are sloughed because demise of the corpus luteum in the non-fertile menstrual cycle is associated with a loss of progesterone secretion.
  • Ovarian follicular maturation occurs progressively resulting in a rise in the circulating levels of estrogen, which in turn leads to new endometrial proliferation.
  • the dominant ovarian follicle undergoes ovulation at mid-cycle, generally between menstrual cycle days 12 to 16 and is converted from a predominantly estrogen source to a predominantly progesterone source (the corpus luteum).
  • the increasing level of progesterone in the blood converts the proliferative endometrium to a secretory phase in which the tissue proliferation has promptly abated, leading to the formation of endometrial glands or organs.
  • the secretory endometrium and the conceptus can interact to bring about implantation (nidation), beginning about 6 to 8 days after fertilization.
  • HCG human chorionic gonadotropin
  • the waning level of progesterone in the blood causes the endometrial tissue to be sloughed. This starts a subsequent menstrual cycle.
  • estrogens are known to decrease follicle stimulating hormone secretion by feedback inhibition. Under certain circumstances, estrogens can also inhibit luteinizing hormone secretion, once again by negative feedback. Under normal circumstances, the spike of circulating estrogen found just prior to ovulation induces the surge of gonadotropic hormones that occurs just prior to and resulting in ovulation. High doses of estrogen immediately post-coitally also can prevent conception probably due to interference with implantation.
  • Progestins can also provide contraception. Endogenous progesterone after estrogen is responsible for the progestational changes of the endometrium and the cyclic changes of cells and tissue in the cervix and the vagina. Administration of progestin makes the cervical mucus thick, tenacious and cellular which is believed to impede spermatozoal transport. Administration of progestin also inhibits luteinizing hormone secretion and blocks ovulation in humans.
  • oral contraception is a pill that combines both an estrogen and a progestin, a so-called combined oral contraceptive preparation.
  • contraceptive preparations that comprise progestin only.
  • the progestin-only preparations have a more varied spectrum of side effects than do the combined preparations, especially more breakthrough bleeding.
  • the combined preparations are the preferred oral contraceptives in use today (Sheth et al., Contraception 25:243, 1982).
  • U.S. Pat. No. 4,390,531 teaches a triphasic regimen in which each phase uses about 20-40 mcg ethinyl estradiol, phases 1 and 3 use 0.3-0.8 norethindrone and phase 2 doubles the amount of the norethindrone. These three phases consume 21 days of a 28 day cycle.
  • European published application 0 226 279 states that this regimen is associated with a high incidence of breakthrough bleeding and substitutes a three phase oral contraceptive regimen using a relatively low amount of ethinyl estradiol (10-50 ⁇ g) and a relatively high amount of norethindrone acetate (0.5-1.5 mg) in each phase provided that the amount of estrogen in any two phases is never the same.
  • a “rest” phase of about 7 days is used in this regimen.
  • U.S. Pat. No. 5,098,714 teaches an osmotic, oral dosage form.
  • One “pill” is administered per day but the administration is, in effect, polyphasic.
  • the dosage form is constructed such that it provides an initial pulse delivery of estrogen and progestin followed by prolonged delivery of estrogen.
  • European published patent application 0 253 607 describes a monophasic contraceptive preparation containing units having 0.008-0.03 mg of ethinyl estradiol and 0.025-0.1 ng of desogestrel (or equivalent) and a regimen where the preparation is administered over a 23-25 day period, preferably 24 days, followed by a 2-5 day pill-free period.
  • the object of this regimen is to provide hormonal replacement therapy and contraceptive protection for the pre-menopausal woman in need thereof by supplying a low dose of an estrogen combined with a “very low dose of a progestogen.”
  • U.S. Pat. No. 5,552,394 describes a method of female contraception which is characterized by a reduced incidence of breakthrough bleeding after the first cycle involves monophasicly administering a combination of estrogen and progestin for 23-25 consecutive days of a 28 day cycle in which the daily amounts of estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively and in which the weight ratio of estrogen to progestin is at least 1:45 calculated as ethinyl estradiol to norethindrone acetate.
  • the regimen enhances compliance by involving fewer stop/start transitions per year and also results in less blood loss in patients with anemia. Having fewer menstrual intervals can enhance lifestyles and convenience.
  • This invention relates to a method of female contraception which is characterized by a reduced number of withdrawal menses per year. More particularly, it relates to a method of female contraception which involves administering, preferably monophasicly, a combination of estrogen and progestin for 60-110 consecutive days followed by 3-10 days of no administration, in which the daily amounts of the estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025-10 mg of norethindrone acetate, respectively.
  • a women in need of contraception is administered a combined dosage form of estrogen and progestin, preferably monophasicly, for 60 to 110 consecutive days, preferably about 80-90 days, followed by an administration free interval of 3 to 10 days, preferably about 5-8 days, in which the daily amounts of estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively.
  • the preferred estrogen and progestins are ethinyl estradiol and norethindrone acetate although other estrogens and progestins can be employed.
  • the weight ratio of these two active ingredients is at least 1:45 and preferably at least 1:50.
  • the preferable amount of ethinyl estradiol is about 10-20 mcg and the preferable amount of the norethindrone acetate is about 0.25-1.5 mg.
  • Other estrogens vary in potency from ethinyl estradiol. For example, 30 mcg of ethinyl estradiol is roughly equivalent to 60 mcg of mestranol or 2,000 mg of 17 ⁇ -estradiol.
  • norethindrone acetate 3.5 mg of norethindrone acetate is roughly equivalent to 1 mg of levonorgestrel or desogestrel and 3-ketodesogestrel and about 0.7 mg of gestodene.
  • the values given above are for the ethinyl estradiol and the norethindrone acetate and if a different estrogen or progestin is employed, an adjustment in the amount based on the relative potency should be made.
  • the correlations in potency between the various estrogens and progestins are known.
  • estrogens include the esters of estradiol, estrone and ethinyl estradiol such as the acetate, sulfate, valerate or benzoate, conjugated equine estrogens, agnostic anti-estrogens, and selective estrogen receptor modulators.
  • the estrogen is administered in the conventional manner by any route where it is active, for instance orally or transdermally. Most estrogens are orally active and that route of administration is therefore preferred. Accordingly, administration forms can be tablets, dragees, capsules or pills which contain the estrogen (and preferably the progestin) and a suitable pharmaceutically acceptable carrier.
  • compositions containing the progestin and a suitable carrier can be solid dosage forms which includes tablets, capsules, cachets, pellets, pills, powders or granules; topical dosage forms which includes solutions, powders, fluid emulsions, fluid suspensions, semi-solids, ointments, pastes, creams, gels or jellies, foams and controlled release depot entities; and parenteral dosage forms which includes solutions, suspensions, emulsions or dry powder comprising an effective amount of progestin as taught in this invention.
  • the active ingredient, the progestin can be contained in such formulations in addition to pharmaceutically acceptable diluents, fillers, disintegrants, binders, lubricants, surfactants, hydrophobic vehicles, water soluble vehicles, emulsifiers, buffers, humectants, moisturizers, solubilizers, preservatives and the like.
  • pharmaceutically acceptable diluents fillers, disintegrants, binders, lubricants, surfactants, hydrophobic vehicles, water soluble vehicles, emulsifiers, buffers, humectants, moisturizers, solubilizers, preservatives and the like.
  • the means and methods for administration are known in the art and an artisan can refer to various pharmacologic references for guidance. For example, “Modern Pharmaceutics”, Banker & Rhodes, Marcel Dekker, Inc. 1979; “Goodman & Gilman's The Pharmaceutical Basis of Therapeutics”, 6th Edition, MacMillan Publishing Co.
  • the pharmaceutical formulations may be provided in kit form containing at least about 60, and preferably at least about 84 tablets, and up to 110 tablets, intended for ingestion on successive days. Preferably administration is daily for at least 60 days using tablets containing the both the estrogen and the progestin and then for at least 3 days with placebo.
  • the studies begin with spontaneous menstruation in a pretreatment control cycle. At the onset of the next spontaneous menses, alternatively, they are assigned to receive on cycle day one an ultra low dose oral contraceptive for either 60 consecutive days, followed by 3 non-treatment days or 84 consecutive days, followed by a 7 non-treatment days. These regimens are continued through three treatment cycles. The study concludes with each group of primates being followed during a post-treatment spontaneous ovarian menstrual cycle.
  • Femoral blood is collected daily and the serum frozen for subsequent RIA of estradiol, progesterone, FSH and LH in the pretreatment and post-treatment cycles and every 3rd day during all three treatment cycles, except daily through the “pill free” interval.
  • Bleeding profiles are kept by daily vaginal swabs, indicating spontaneous menstruation, withdrawal bleeding, breakthrough bleeding, or withdrawal amenorrhea. Breakthrough bleeding is defined as detectable blood in the vagina outside of the first 8 days after the last dose of oral contraceptive or the onset of spontaneous menses in non-treatment cycles.
  • the medication is adjusted to fit the smaller (than human) body weight of these laboratory primates.
  • the dose of ethinyl estradiol is 1.2 ⁇ g/day, while the dose of norethindrone acetate is 0.06 mg/day.
  • This “in-house” reformulation is achieved by grinding to powder a commercially available monophasic pill (Loestrin 1/20, Parke Davis, Morris Plains, N.J.), which originally contained 1 mg of norethindrone acetate and 20 ⁇ g of ethinyl estradiol per tablet, contained in a conventional 21 day pack along with 7 iron-containing placebos.
  • the daily dose received by the monkeys is about 12 ⁇ g of ethinyl estradiol and 0.6 mg of norethindrone acetate.
  • this ultra low dose oral contraceptive formulation presented a 40% reduction in daily estrogen-progestin exposure as compared to one of the lowest estrogen dose combination oral contraceptives commercially available today in America or Europe.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Confectionery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of female contraception involves administering a combination of estrogen and progestin for 60-110 consecutive days in which the daily amounts of estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively. The advantages include less menstrual bleeding, less patient anemia, less total exposure to medication, higher compliance rates and more lifestyle convenience for patients.

Description

BACKGROUND OF THE INVENTION
The ovarian/menstrual cycle is a complex event characterized by an estrogen rich follicular phase and, after ovulation, a progesterone rich luteal phase. Each has a duration of approximately 14 days resulting in an intermenstrual interval of about 28 days. The endometrial tissue responds to the changes in hormonal milieu.
The onset of menstruation is the beginning of a new menstrual cycle and is counted as day 1. During a span of about 5 to 7 days, the superficial layers of the endometrium, which grew and developed during the antecedent ovarian/menstrual cycle, are sloughed because demise of the corpus luteum in the non-fertile menstrual cycle is associated with a loss of progesterone secretion. Ovarian follicular maturation occurs progressively resulting in a rise in the circulating levels of estrogen, which in turn leads to new endometrial proliferation.
The dominant ovarian follicle undergoes ovulation at mid-cycle, generally between menstrual cycle days 12 to 16 and is converted from a predominantly estrogen source to a predominantly progesterone source (the corpus luteum). The increasing level of progesterone in the blood converts the proliferative endometrium to a secretory phase in which the tissue proliferation has promptly abated, leading to the formation of endometrial glands or organs. When the ovulated oocyte is viably fertilized and continues its progressive embryonic cleavage, the secretory endometrium and the conceptus can interact to bring about implantation (nidation), beginning about 6 to 8 days after fertilization.
If an ongoing pregnancy is to be established via implantation, the embryo will attach and burrow into the secretory endometrium and begin to produce human chorionic gonadotropin (HCG). The HCG in turn stimulates extended corpus luteum function, i.e. the progesterone production remains elevated, and menses does not occur in the fertile menstrual cycle. Pregnancy is then established.
In the non-fertile menstrual cycle, the waning level of progesterone in the blood causes the endometrial tissue to be sloughed. This starts a subsequent menstrual cycle.
Because endometrial proliferation serves to prepare the uterus for an impending pregnancy, manipulation of hormones and of the uterine environment can provide contraception. For example, estrogens are known to decrease follicle stimulating hormone secretion by feedback inhibition. Under certain circumstances, estrogens can also inhibit luteinizing hormone secretion, once again by negative feedback. Under normal circumstances, the spike of circulating estrogen found just prior to ovulation induces the surge of gonadotropic hormones that occurs just prior to and resulting in ovulation. High doses of estrogen immediately post-coitally also can prevent conception probably due to interference with implantation.
Progestins can also provide contraception. Endogenous progesterone after estrogen is responsible for the progestational changes of the endometrium and the cyclic changes of cells and tissue in the cervix and the vagina. Administration of progestin makes the cervical mucus thick, tenacious and cellular which is believed to impede spermatozoal transport. Administration of progestin also inhibits luteinizing hormone secretion and blocks ovulation in humans.
The most prevalent form of oral contraception is a pill that combines both an estrogen and a progestin, a so-called combined oral contraceptive preparation.
Alternatively, there are contraceptive preparations that comprise progestin only. However, the progestin-only preparations have a more varied spectrum of side effects than do the combined preparations, especially more breakthrough bleeding. As a result, the combined preparations are the preferred oral contraceptives in use today (Sheth et al., Contraception 25:243, 1982).
Whereas the conventional 21 day pill packs with a 7 day “pill free” or placebo interval worked well when oral contraceptives were of higher dosage, as the doses have come down, for both the estrogen and progestin components, bleeding problems have increased in frequency, especially in the early months of oral contraceptive use, but even persistently so in some patients.
Since the advent of combined estrogen-progestin medications as oral contraceptives, there has been a steady downward adjustment of the daily estrogen dosage. Concurrently, where exposure to the progestin component has also been lowered, reduced androgenicity has remained an ongoing priority. Together these adaptions in formulation have been presented in a variety of regimens, both monophasic and multiphasic. Each have their own advantages and disadvantages. All-in-all, today's oral contraceptives are much safer with regard to the incidence and severity of estrogen-linked clotting disorders as well as the suggested cumulative impact of more “lipid friendly” progestins that maintain the potentially advantageous high density lipoprotein cholesterol levels in circulation.
U.S. Pat. No. 4,390,531 teaches a triphasic regimen in which each phase uses about 20-40 mcg ethinyl estradiol, phases 1 and 3 use 0.3-0.8 norethindrone and phase 2 doubles the amount of the norethindrone. These three phases consume 21 days of a 28 day cycle. European published application 0 226 279 states that this regimen is associated with a high incidence of breakthrough bleeding and substitutes a three phase oral contraceptive regimen using a relatively low amount of ethinyl estradiol (10-50 μg) and a relatively high amount of norethindrone acetate (0.5-1.5 mg) in each phase provided that the amount of estrogen in any two phases is never the same. A “rest” phase of about 7 days is used in this regimen.
U.S. Pat. No. 5,098,714 teaches an osmotic, oral dosage form. One “pill” is administered per day but the administration is, in effect, polyphasic. The dosage form is constructed such that it provides an initial pulse delivery of estrogen and progestin followed by prolonged delivery of estrogen.
European published patent application 0 253 607 describes a monophasic contraceptive preparation containing units having 0.008-0.03 mg of ethinyl estradiol and 0.025-0.1 ng of desogestrel (or equivalent) and a regimen where the preparation is administered over a 23-25 day period, preferably 24 days, followed by a 2-5 day pill-free period. The object of this regimen is to provide hormonal replacement therapy and contraceptive protection for the pre-menopausal woman in need thereof by supplying a low dose of an estrogen combined with a “very low dose of a progestogen.”
In 1989, the accumulating data from the evolution of oral contraceptive pill formulations containing only 20-35 μg of estrogen per day spurred the Food and Drug Administration's Fertility and Maternal Health Drugs Advisory Committee to recommend indication of low dose oral contraceptives for healthy, non-smoking women even during the perimenopausal years, such as, for instance, ages 35-50. In Japan, oral contraceptives are being evaluated for safety and efficacy, as well as social acceptability, for the first time.
U.S. Pat. No. 5,552,394 describes a method of female contraception which is characterized by a reduced incidence of breakthrough bleeding after the first cycle involves monophasicly administering a combination of estrogen and progestin for 23-25 consecutive days of a 28 day cycle in which the daily amounts of estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively and in which the weight ratio of estrogen to progestin is at least 1:45 calculated as ethinyl estradiol to norethindrone acetate.
In establishing a estrogen-progestin regimen for oral contraceptives, two principal issues must be confronted. First, efficacy must be maintained and second, there must be avoidance of further erosion in the control of endometrial bleeding. In general, even the lowest dose oral contraceptive products commercially available have demonstrated efficacy but the overall instances of bleeding control problems has increased as the doses were reduced, as manifest both in breakthrough bleeding (untimely flow or spotting) or withdrawal amenorrhea during the “pill free” week (expected menses).
It is the object of the present invention to provide a new estrogen-progestin combination and/or regimen for oral contraceptive use which maintains the efficacy and provides enhanced control of endometrial bleeding. The regimen enhances compliance by involving fewer stop/start transitions per year and also results in less blood loss in patients with anemia. Having fewer menstrual intervals can enhance lifestyles and convenience. This and other objects of the invention will become apparent to those skilled in the art from the following detailed description.
SUMMARY OF THE INVENTION
This invention relates to a method of female contraception which is characterized by a reduced number of withdrawal menses per year. More particularly, it relates to a method of female contraception which involves administering, preferably monophasicly, a combination of estrogen and progestin for 60-110 consecutive days followed by 3-10 days of no administration, in which the daily amounts of the estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025-10 mg of norethindrone acetate, respectively.
DESCRIPTION OF INVENTION
In accordance with the present invention, a women in need of contraception is administered a combined dosage form of estrogen and progestin, preferably monophasicly, for 60 to 110 consecutive days, preferably about 80-90 days, followed by an administration free interval of 3 to 10 days, preferably about 5-8 days, in which the daily amounts of estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively. On a schedule of 84 days administration followed by 7 pill free days, there are only four treatment and menstrual cycles per year.
The preferred estrogen and progestins are ethinyl estradiol and norethindrone acetate although other estrogens and progestins can be employed. The weight ratio of these two active ingredients is at least 1:45 and preferably at least 1:50. The preferable amount of ethinyl estradiol is about 10-20 mcg and the preferable amount of the norethindrone acetate is about 0.25-1.5 mg. Other estrogens vary in potency from ethinyl estradiol. For example, 30 mcg of ethinyl estradiol is roughly equivalent to 60 mcg of mestranol or 2,000 mg of 17 β-estradiol. Likewise, other progestins vary in potency from norethindrone acetate. Thus, 3.5 mg of norethindrone acetate is roughly equivalent to 1 mg of levonorgestrel or desogestrel and 3-ketodesogestrel and about 0.7 mg of gestodene. The values given above are for the ethinyl estradiol and the norethindrone acetate and if a different estrogen or progestin is employed, an adjustment in the amount based on the relative potency should be made. The correlations in potency between the various estrogens and progestins are known.
Other useable estrogens include the esters of estradiol, estrone and ethinyl estradiol such as the acetate, sulfate, valerate or benzoate, conjugated equine estrogens, agnostic anti-estrogens, and selective estrogen receptor modulators. The estrogen is administered in the conventional manner by any route where it is active, for instance orally or transdermally. Most estrogens are orally active and that route of administration is therefore preferred. Accordingly, administration forms can be tablets, dragees, capsules or pills which contain the estrogen (and preferably the progestin) and a suitable pharmaceutically acceptable carrier.
Pharmaceutical formulations containing the progestin and a suitable carrier can be solid dosage forms which includes tablets, capsules, cachets, pellets, pills, powders or granules; topical dosage forms which includes solutions, powders, fluid emulsions, fluid suspensions, semi-solids, ointments, pastes, creams, gels or jellies, foams and controlled release depot entities; and parenteral dosage forms which includes solutions, suspensions, emulsions or dry powder comprising an effective amount of progestin as taught in this invention. It is known in the art that the active ingredient, the progestin, can be contained in such formulations in addition to pharmaceutically acceptable diluents, fillers, disintegrants, binders, lubricants, surfactants, hydrophobic vehicles, water soluble vehicles, emulsifiers, buffers, humectants, moisturizers, solubilizers, preservatives and the like. The means and methods for administration are known in the art and an artisan can refer to various pharmacologic references for guidance. For example, “Modern Pharmaceutics”, Banker & Rhodes, Marcel Dekker, Inc. 1979; “Goodman & Gilman's The Pharmaceutical Basis of Therapeutics”, 6th Edition, MacMillan Publishing Co., New York 1980 can be consulted.
The pharmaceutical formulations may be provided in kit form containing at least about 60, and preferably at least about 84 tablets, and up to 110 tablets, intended for ingestion on successive days. Preferably administration is daily for at least 60 days using tablets containing the both the estrogen and the progestin and then for at least 3 days with placebo.
In order to further illustrate the present invention, specific examples are set forth below. It will be appreciated, however, that these examples are illustrative only and are not intended to limit the scope of the invention.
EXAMPLE 1
A study is carried out at a fully accredited animal research facility which complies through its animal care and use committee with the review standards set forth in the National Institute of Health's “Guide for Care and Use of Laboratory Animals”, the Public Health Services' “Principles for the Care and Use of Laboratory Animals”, and the United States Department of Agriculture's Implementation Regulations of the 1985 Amendments for the Animal Welfare Act.
Ten adult female cynomolgus monkeys (macaca fasicularis) having regular presumably ovulatory menstrual cycles (28.9±3.1 days for the month prior to study entry) are selected. Their duration of spontaneous menses is 3.4±1.4 days. Mean body weight of the monkeys is 4.9±1.1 kg (X±SEM). They are housed individually in a controlled environment (12 hours of light and 23° C.). Their diet is a commercial primate food (Purina, St. Louis, Mo.) with water ad libitum.
The monkeys are divided at random into two groups (N=5 each). The studies begin with spontaneous menstruation in a pretreatment control cycle. At the onset of the next spontaneous menses, alternatively, they are assigned to receive on cycle day one an ultra low dose oral contraceptive for either 60 consecutive days, followed by 3 non-treatment days or 84 consecutive days, followed by a 7 non-treatment days. These regimens are continued through three treatment cycles. The study concludes with each group of primates being followed during a post-treatment spontaneous ovarian menstrual cycle.
Femoral blood is collected daily and the serum frozen for subsequent RIA of estradiol, progesterone, FSH and LH in the pretreatment and post-treatment cycles and every 3rd day during all three treatment cycles, except daily through the “pill free” interval. Bleeding profiles are kept by daily vaginal swabs, indicating spontaneous menstruation, withdrawal bleeding, breakthrough bleeding, or withdrawal amenorrhea. Breakthrough bleeding is defined as detectable blood in the vagina outside of the first 8 days after the last dose of oral contraceptive or the onset of spontaneous menses in non-treatment cycles.
Since the objective is to test an ultra low dose oral contraceptive, the medication is adjusted to fit the smaller (than human) body weight of these laboratory primates. The dose of ethinyl estradiol is 1.2 μg/day, while the dose of norethindrone acetate is 0.06 mg/day. This “in-house” reformulation is achieved by grinding to powder a commercially available monophasic pill (Loestrin 1/20, Parke Davis, Morris Plains, N.J.), which originally contained 1 mg of norethindrone acetate and 20 μg of ethinyl estradiol per tablet, contained in a conventional 21 day pack along with 7 iron-containing placebos.
In terms of comparison to human dose equivalents, the daily dose received by the monkeys (with a monkey's body weight about 5 kg and a woman's at 50 kg) is about 12 μg of ethinyl estradiol and 0.6 mg of norethindrone acetate. Thus, this ultra low dose oral contraceptive formulation presented a 40% reduction in daily estrogen-progestin exposure as compared to one of the lowest estrogen dose combination oral contraceptives commercially available today in America or Europe. Taking into account that when a continuous 84 day ultra low dose regimen plus a 7 dy pill free interval was used, versus the traditional 21+7 day protocol, that there would be 63 more doses on an annualized basis, still the exposure to medication was reduced by more than 26% yearly, compared to the commercial product Loestrin 1/20.
EXAMPLES 2-5
The example 1 procedure is repeated using the following combinations of estrogen and progestin:
Example Estrogen Progestin Treatment Days
2 mestranol levo- 84
norgestrel
3 17-beta- 3-keto- 110
estradiol desogestrel
4 ethinyl desogestrel 80
estradiol
5 mestranol gestodone 60
Application of the compounds, compositions and methods of the present invention for the medical or pharmaceutical uses described can be accomplished by any clinical, medical, and pharmaceutical methods and techniques as are presently or prospectively known to those skilled in the art. It will therefore be appreciated that the various embodiments which have been described above are intended to illustrate the invention and various changes and modifications can be made in the inventive method without departing from the spirit and scope thereof.

Claims (12)

1. A method of extended female contraception that reduces the number of menstrual periods per year, which comprises orally monophasicly administering to a pre-menopausal female a combination of estrogen and progestin for 60-110 84 consecutive days in which the daily amounts of estrogen and progestin are equivalent to about 5-35 30 mcg of ethinyl estradiol and about 0.025 to 10 0.25-1.5 mg of norethindrone acetate, respectively, following followed by non-administration administration of a placebo for a period of 3-10 5-8 days, wherein the combination of estrogen and progestin and the placebo are packaged together in a kit, and wherein the method of female contraception reduces the number of menstrual periods per year to four when the method is practiced for at least one year.
2. The method of claim 1 in which the daily amount of estrogen is equivalent to about 10 to 20 mcg of ethinyl estradiol.
3. The method of claim 2 in which the daily amount of progestin is equivalent to 0.25-1.5 mg of norethindrone acetate.
4. The method of claim 3 in which the combination is administered for at least 80 consecutive days.
5. The method of claim 4 in which the estrogen is ethinyl estradiol.
6. The method of claim 5 in which the progestin is norethindrone acetate.
7. The method of claim 1 in which the daily amount of progestin is equivalent to 0.25-1.5 mg of norethindrone acetate.
8. The method of claim 1 in which the combination is administered for at least 80 consecutive days.
9. The method of claim 1 in which the estrogen is ethinyl estradiol.
10. The method of claim 1 in which the progestin is norethindrone acetate.
11. The method of claim 1 in which the daily amount of estrogen is up to 30 mcg of ethinyl estadiol.
12. The method of claim 9 in which the progestin is levonorgestrel.
US10/893,795 1997-06-23 2004-07-19 Methods of extended use oral contraception Expired - Lifetime USRE39861E1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/880,419 US5898032A (en) 1997-06-23 1997-06-23 Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
CA002256977A CA2256977C (en) 1997-06-23 1998-12-23 Methods of extended use oral contraception

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/880,419 Reissue US5898032A (en) 1997-06-23 1997-06-23 Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy

Publications (1)

Publication Number Publication Date
USRE39861E1 true USRE39861E1 (en) 2007-09-25

Family

ID=32043766

Family Applications (2)

Application Number Title Priority Date Filing Date
US08/880,419 Ceased US5898032A (en) 1997-06-23 1997-06-23 Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US10/893,795 Expired - Lifetime USRE39861E1 (en) 1997-06-23 2004-07-19 Methods of extended use oral contraception

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08/880,419 Ceased US5898032A (en) 1997-06-23 1997-06-23 Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy

Country Status (10)

Country Link
US (2) US5898032A (en)
EP (1) EP0911029B1 (en)
JP (1) JPH1129481A (en)
AT (1) ATE216241T1 (en)
CA (1) CA2256977C (en)
DE (1) DE69804918T2 (en)
DK (1) DK0911029T3 (en)
ES (1) ES2175650T3 (en)
NO (1) NO982815L (en)
PT (1) PT911029E (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220152A1 (en) * 2003-05-02 2004-11-04 Ben-Maimon Carole S. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20060135496A1 (en) * 2004-10-07 2006-06-22 Duramed Pharmaceuticals, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US7615545B2 (en) 2001-12-05 2009-11-10 Duramed Pharmaceuticals, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US20100120707A1 (en) * 2008-09-16 2010-05-13 Playtex Products, Llc Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administering same
US20110124611A1 (en) * 2003-07-16 2011-05-26 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
US9192614B2 (en) 2008-10-08 2015-11-24 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
US9198876B2 (en) 2008-10-08 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
US9198919B2 (en) 2008-10-08 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
US9198920B2 (en) 2009-03-27 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19549264A1 (en) * 1995-12-23 1997-06-26 Schering Ag Contraception procedure and kit
WO2001030355A1 (en) 1999-10-25 2001-05-03 Laboratoire Theramex Contraceptive medicine based on a progestational agent and an oestrogen and preparation method
FR2754179B1 (en) 1996-10-08 1998-12-24 Theramex NOVEL HORMONONAL COMPOSITION AND ITS USE
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6251956B1 (en) 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
DE19739916C2 (en) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Use of a combination of a progestogen and an estrogen for the continuous inhibition of ovulation and possibly simultaneous treatment and / or prophylaxis of tumors of the mammary glands
WO2000028995A1 (en) * 1998-11-12 2000-05-25 Warner Chilcott Laboratories Ireland Limited Graduated progestin contraceptive
US6925809B2 (en) 1999-02-26 2005-08-09 R. Jan Mowill Gas turbine engine fuel/air premixers with variable geometry exit and method for controlling exit velocities
US7297688B2 (en) 2000-06-08 2007-11-20 Wyeth Starter kit for low dose oral contraceptives
DE10045380A1 (en) * 2000-09-14 2002-04-04 Schering Ag Contraception procedure and dosage form
RU2358699C2 (en) * 2001-06-18 2009-06-20 Ноувен Фамэсьютикэлз, Инк. Percutaneous drug delivery composition (versions), method of production and application
US20030018018A1 (en) * 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
EP1663815B1 (en) * 2003-09-04 2010-07-21 Pharmadesign Inc. Case with pill receiving sleeves for storing and dispensing pills
JP2007507534A (en) * 2003-10-01 2007-03-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Sustained three-phase contraception
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
ES2397983T3 (en) 2004-03-19 2013-03-12 Warner Chilcott Company, Llc Long-cycle multiphase oral contraceptive procedure
DE102004019743B4 (en) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Multiphase preparation for contraception based on natural estrogen
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
DE102004026671A1 (en) * 2004-05-28 2005-12-15 Grünenthal GmbH Dosage form for hormonal contraception
DE102004026670A1 (en) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonal contraceptive containing a combination of ethinylestradiol and chlormadinone acetate
DE102004026679A1 (en) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonal contraceptive containing a combination of ethinylestradiol and chlormadinone acetate
US8501720B2 (en) * 2004-07-30 2013-08-06 Bayer Pharma AG Method for treatment of dysmenorrhea
EP1655031A1 (en) 2004-10-08 2006-05-10 Schering AG Use of dienogest in fixed extended cycle hormonal contraceptives
US20060079491A1 (en) * 2004-10-08 2006-04-13 Andreas Sachse Method of female hormonal contraception using a fixed extended cycle hormonal preparation containing dienogest and ethinyl estradiol
US7704984B2 (en) 2005-04-22 2010-04-27 Warner Chilcott Company, Llc Extended estrogen dosing contraceptive regimen
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1983999A4 (en) * 2006-01-27 2010-10-20 Teva Womens Health Inc Regimens for treatment of conditions related to estrogen deficiency
WO2007106264A2 (en) * 2006-03-02 2007-09-20 Warner Chilcott Company, Inc. Extended cycle multiphasic oral contraceptive method
EP1930010A1 (en) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Application of estradiol valerate or 17ß-estradiol in combination with dienogest for oral therapy to maintain and/or increase the female libido
AT12800U1 (en) * 2007-11-05 2012-11-15 Bayer Schering Pharma Ag A pharmaceutical preparation for use in the oral contraception of lactose intolerant women
AU2016264137B2 (en) * 2015-05-18 2021-08-19 Agile Therapeutics, Inc. Contraceptive compositions and methods for improved efficacy and modulation of side effects
US12138270B2 (en) 2021-09-07 2024-11-12 Millicent Pharma Limited Contraceptive regimen including reduced level of estrogen
CA3234836A1 (en) * 2021-09-07 2023-03-16 Millicent Pharma Limited Contraceptive regimen including reduced level of estrogen

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145416A (en) 1976-06-23 1979-03-20 Schering, A.G. Novel agents and novel methods for treatment of climacteric disturbances
US4390531A (en) * 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
EP0253607A1 (en) 1986-07-15 1988-01-20 American Home Products Corporation Combination dosage form for premenopausal women
US4962098A (en) 1987-06-15 1990-10-09 Warner-Lambert Company Graduated estrogen contraceptive
US5098714A (en) * 1989-11-16 1992-03-24 Alza Corporation Osmotic, oral dosage form for fertility control
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
US5208225A (en) 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
WO1993017686A1 (en) 1992-03-02 1993-09-16 Schering Aktiengesellschaft Estrogen/progestin/antiprogestin method and kit for oral contraception and regulating menses
US5552394A (en) 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
WO1997006807A2 (en) 1995-08-17 1997-02-27 Schering Aktiengesellschaft Contraceptive combined preparation, kits containing the same and contraceptive method using this combined preparation
WO1998004246A2 (en) 1996-07-26 1998-02-05 American Home Prod Triphasic contraceptive method and kit comprising a combination of a progestin and estrogen
US5756490A (en) * 1994-03-30 1998-05-26 Schering Aktiengesellschaft Pharmaceutical combination preparation for hormonal contraception
USRE36247E (en) 1983-08-05 1999-07-06 Woco Investments, Ltd. Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
WO2000038691A1 (en) 1998-12-23 2000-07-06 Ortho-Mcneil Pharmaceutical, Inc. Triphasic oral contraceptive
EP0911029B1 (en) 1997-06-23 2002-04-17 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
USRE37838E1 (en) 1993-12-22 2002-09-10 Schering Aktiengesellschaft Composition for contraception
US6500814B1 (en) 1997-09-11 2002-12-31 Wyeth Pharmaceuticals Hormonal contraceptive
US20030018018A1 (en) 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
US20030139381A1 (en) 2001-12-05 2003-07-24 Barr Laboratories, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
WO2004080442A1 (en) 2003-03-11 2004-09-23 Janssen Pharmaceutica N.V. Extended transdermal contraceptive regimens
US20040220152A1 (en) 2003-05-02 2004-11-04 Ben-Maimon Carole S. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20040222123A1 (en) 2003-05-06 2004-11-11 Barr Laboratories, Inc. Kit for pharmaceuticals
US20040251301A1 (en) 2003-05-05 2004-12-16 Niemann Amy C. Device for calculating anticipated days for menstruation
US20050051454A1 (en) 2003-09-04 2005-03-10 Coe Matthew T. Case with pill receiving sleeves for storing and dispensing pills
WO2005032558A1 (en) 2003-10-01 2005-04-14 Janssen Pharmaceutica N.V. Extended triphasic contraceptive regimens
US20050143359A1 (en) 2003-07-16 2005-06-30 Bell Robert G. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19525017A1 (en) * 1995-06-28 1997-01-02 Schering Ag Pharmaceutical combination preparation, kit and method for hormonal contraception

Patent Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145416A (en) 1976-06-23 1979-03-20 Schering, A.G. Novel agents and novel methods for treatment of climacteric disturbances
US4390531A (en) * 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
USRE36247E (en) 1983-08-05 1999-07-06 Woco Investments, Ltd. Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US5208225A (en) 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
EP0253607A1 (en) 1986-07-15 1988-01-20 American Home Products Corporation Combination dosage form for premenopausal women
US4962098A (en) 1987-06-15 1990-10-09 Warner-Lambert Company Graduated estrogen contraceptive
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
US5098714A (en) * 1989-11-16 1992-03-24 Alza Corporation Osmotic, oral dosage form for fertility control
WO1993017686A1 (en) 1992-03-02 1993-09-16 Schering Aktiengesellschaft Estrogen/progestin/antiprogestin method and kit for oral contraception and regulating menses
USRE37838E1 (en) 1993-12-22 2002-09-10 Schering Aktiengesellschaft Composition for contraception
US5756490A (en) * 1994-03-30 1998-05-26 Schering Aktiengesellschaft Pharmaceutical combination preparation for hormonal contraception
US5552394A (en) 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
WO1997006807A2 (en) 1995-08-17 1997-02-27 Schering Aktiengesellschaft Contraceptive combined preparation, kits containing the same and contraceptive method using this combined preparation
US20050064031A1 (en) 1995-08-17 2005-03-24 Klaus Stockemann Combination contraceptive, kits that contain the latter, and a method that uses the latter
WO1998004246A2 (en) 1996-07-26 1998-02-05 American Home Prod Triphasic contraceptive method and kit comprising a combination of a progestin and estrogen
EP0911029B1 (en) 1997-06-23 2002-04-17 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6500814B1 (en) 1997-09-11 2002-12-31 Wyeth Pharmaceuticals Hormonal contraceptive
WO2000038691A1 (en) 1998-12-23 2000-07-06 Ortho-Mcneil Pharmaceutical, Inc. Triphasic oral contraceptive
US20030018018A1 (en) 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
US20030139381A1 (en) 2001-12-05 2003-07-24 Barr Laboratories, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
WO2004080442A1 (en) 2003-03-11 2004-09-23 Janssen Pharmaceutica N.V. Extended transdermal contraceptive regimens
US20040220152A1 (en) 2003-05-02 2004-11-04 Ben-Maimon Carole S. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20040251301A1 (en) 2003-05-05 2004-12-16 Niemann Amy C. Device for calculating anticipated days for menstruation
US20040222123A1 (en) 2003-05-06 2004-11-11 Barr Laboratories, Inc. Kit for pharmaceuticals
US20050143359A1 (en) 2003-07-16 2005-06-30 Bell Robert G. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
US20050051454A1 (en) 2003-09-04 2005-03-10 Coe Matthew T. Case with pill receiving sleeves for storing and dispensing pills
WO2005032558A1 (en) 2003-10-01 2005-04-14 Janssen Pharmaceutica N.V. Extended triphasic contraceptive regimens

Non-Patent Citations (25)

* Cited by examiner, † Cited by third party
Title
"Headaches: OCs are 'guilty by association'," Contraceptive Technology Update 14(7):109-112, Thomson American Health Consultants (1993).
Adams Hillard, P.J., "Oral contraception noncompliance: The extent of the problem," Adv. Contracep. 8(Suppl. 1):13-20, Kluwer Academic Publishers (1992).
Cachrimanidou et al., Contraception, 48, 205-216 (1993). *
Coffee, A., "Hormone-Based Contraception: The Extended Cycle Regimen," Supplement to Drug Topics, pp. 3-15, Advanstar Communications, Inc. (Jan. 2004).
Davies et al., Contraception, 46(3), 269-278 (1992). *
Dickey, R.P., "Oral Contraception: Realizing the Promise by Overcoming the Pitfalls," Individualizing Oral Contraceptive Therapy, OBG Management Supplement, pp. 2-6, Watson Pharma, Inc. (Oct. 2000).
Facts and Comparisons, chapter 3, pp. 108b-108e (1985). *
Goldzieher, J.W., "Use and Misuse of the Term Potency with Respect to Oral Contraceptives," J. Reproductive Med. 31:533-539, The Journal of Reproductive Medicine, Inc. (1986).
Hipkin, L., Col., "The Induction of Amenorrhoea," J.R. Army Med. Corps 138:15-18, Royal Army Medical Corps (1992).
King, R.J.B., and Whitehead, M.I., "Assessment of the potency of orally administered progestins in women," Fertility and Sterility 46:1062-1066, Elsevier for the American Society for Reproductive Medicine (1986).
Koetsawang, S., et al., "A Randomized, Double-Blind Study of Six Combined Oral Contraceptives," Contraception 25:231-241, Elsevier (1982).
Kornaat, H., et al., "The Acceptance of a 7-Week Cycle with a Modern Low-Dose Oral Contraceptive (Minulet(R))," Contraception 45:119-127, Elsevier (1992).
Kornaat, H., et al., "The Acceptance of a 7-Week Cycle with a Modern Low-Dose Oral Contraceptive (Minulet®)," Contraception 45:119-127, Elsevier (1992).
Kovac et al. The British Journal of Family Planning, 19: 274-275 (1994). *
Kuhl, H., "Comparative Pharmacology of Newer Progestogens," Drugs 51:189-215, ADIS International Ltd. (1996).
Loudon et al., British Medical Journal,2, 487-490 (1977). *
Mashchak, C.A., et al., "Comparison of pharmacodynamic properties of various estrogen formulations," Am. J. Obstet. Gynecol. 144:511-518, The C.V. Mosby Co. (1982).
Miller, L., and Notter, K.M., "Menstrual Reduction With Extended Use of Combination Oral Contraceptive Pills: Randomized Controlled Trial," Obstet. Gynecol. 98:771-778, Lippincott, Williams & Wilkins (Nov. 2001).
Phillips, A., et al., "A Comparison of the Potencies and Activities of Progestogens Used in Contraceptives," Contraception 36:181-192, Geron-X, Inc. (1987).
Piper, J.M., and Kennedy, D.L., "Oral Contraceptives in the United States: Trends in Content and Potency," Intl. J. Epidemiology 16:215-221, Oxford University Press (1987).
Rosenberg, M.J. and Waugh, M.S., "Oral contraceptive discontinuation: A prospective evaluation of frequency and reasons," Am. J. Obstet. Gynecol. 179:577-582, Mosby, Inc. (1998).
Shearman, R.P., "Oral contraceptive agents," Med. J. Australia 144:201-205, Australasian Medical Publishing (1986).
Sheth, A., et al., "A Randomized, Double-Blind Study of Two Combined and Two Progestogen-Only Oral Contraceptives," Contraception 25:243-252, Elsevier (1982).
Sulak, P.J., "Should your patient be on extended-use OCs?" Contemporary OB/GYN 48:35-46, Thomson Medical Economics (Sep. 2003).
Sulak, P.J., et al., "Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms," Am. J. Obstet. Gynecol. 186:1142-1149, Mosby, Inc. (Jun. 2002).

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100298279A1 (en) * 2001-12-05 2010-11-25 Bell Robert G Oral Contraceptives to Prevent Pregnancy and Diminish Premenstrual Symptomatology
US8338396B2 (en) 2001-12-05 2012-12-25 Teva Women's Health, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US8680084B2 (en) 2001-12-05 2014-03-25 Teva Women's Health, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US7858605B2 (en) 2001-12-05 2010-12-28 Teva Women's Health, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US7615545B2 (en) 2001-12-05 2009-11-10 Duramed Pharmaceuticals, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US20040220152A1 (en) * 2003-05-02 2004-11-04 Ben-Maimon Carole S. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US7772219B2 (en) 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20110124611A1 (en) * 2003-07-16 2011-05-26 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
US20080125402A1 (en) * 2004-10-07 2008-05-29 Duramed Pharmaceuticals, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20060135496A1 (en) * 2004-10-07 2006-06-22 Duramed Pharmaceuticals, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
US8415332B2 (en) 2004-10-07 2013-04-09 TEVA Woman's Health, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
US8450299B2 (en) 2004-10-07 2013-05-28 Teva Womans's Health, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
US20100120707A1 (en) * 2008-09-16 2010-05-13 Playtex Products, Llc Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administering same
US9192614B2 (en) 2008-10-08 2015-11-24 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
US9198876B2 (en) 2008-10-08 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
US9198919B2 (en) 2008-10-08 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
US9775847B2 (en) 2008-10-08 2017-10-03 Agile Therapeutics, Inc. Transdermal contraceptive hormones delivery
US9775848B2 (en) 2008-10-08 2017-10-03 Agile Therapeutics, Inc. Transdermal contraceptive hormones delivery
US9782419B2 (en) 2008-10-08 2017-10-10 Agile Therapeutics, Inc. Transdermal contraceptive hormones delivery
US9198920B2 (en) 2009-03-27 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
US9775817B2 (en) 2009-03-27 2017-10-03 Agile Therapeutics, Inc. Transdermal contraceptive hormones delivery

Also Published As

Publication number Publication date
EP0911029A3 (en) 2000-03-29
JPH1129481A (en) 1999-02-02
CA2256977A1 (en) 2000-06-23
ES2175650T3 (en) 2002-11-16
US5898032A (en) 1999-04-27
NO982815D0 (en) 1998-06-18
CA2256977C (en) 2008-11-25
EP0911029A2 (en) 1999-04-28
DE69804918D1 (en) 2002-05-23
ATE216241T1 (en) 2002-05-15
NO982815L (en) 1998-12-28
EP0911029B1 (en) 2002-04-17
PT911029E (en) 2002-09-30
DK0911029T3 (en) 2002-06-17
DE69804918T2 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
USRE39861E1 (en) Methods of extended use oral contraception
US5552394A (en) Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
USRE43916E1 (en) Composition for contraception
US5382573A (en) Hormone preparation and method
CA2188907C (en) Combination compound for contraception based on natural estrogen
JP3001216B2 (en) Contraceptive systems and methods
EP0559240B1 (en) Contraceptive packages containing oestrogen and progestin
US7772219B2 (en) Methods of hormonal treatment utilizing extended cycle contraceptive regimens
ZA200404249B (en) Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US20030018018A1 (en) Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
JP2000515888A (en) Birth control pills
WO2005092346A1 (en) Using combination of estrogen and progestin with ultra low dose for long term oral contraception
EP1159965B1 (en) Use of a progesterone receptor antagonist for preventing or inhibiting fertilization
WO1999025360A2 (en) Progestogen-antiprogestogen regimens
CA2596416A1 (en) Methods of extended use oral contraception
JP2007197459A (en) Ultra low dose contraceptive with less menstrual bleeding and sustained efficacy
Kovacs Luteal contraception
IE84449B1 (en) Contraceptive packages containing oestrogen and progestin

Legal Events

Date Code Title Description
AS Assignment

Owner name: BARR LABORATORIES, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EASTERN VIRGINIA MEDICAL SCHOOL;REEL/FRAME:016513/0189

Effective date: 20041227

Owner name: DURAMED PHARMACEUTICALS, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BARR LABORATORIES, INC.;REEL/FRAME:016500/0815

Effective date: 20041213

CC Certificate of correction
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: TEVA WOMEN'S HEALTH, INC., NEW JERSEY

Free format text: CHANGE OF NAME;ASSIGNOR:DURAMED PHARMACEUTICALS, INC.;REEL/FRAME:024402/0984

Effective date: 20090422

Owner name: TEVA WOMEN'S HEALTH, INC.,NEW JERSEY

Free format text: CHANGE OF NAME;ASSIGNOR:DURAMED PHARMACEUTICALS, INC.;REEL/FRAME:024402/0984

Effective date: 20090422

FPAY Fee payment

Year of fee payment: 12